The effects of ABCB1 3′-untranslated region variants on mRNA stability

Drug Metabolism and Disposition

Volumn 36, Issue 1, 2008, Pages 10-15

  Gow, Jason M ^a   Chinn, Leslie W ^a   Kroetz, Deanna L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RH584E ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1;

3' UNTRANSLATED REGION; ALLELE; ARTICLE; CALCULATION; CELL STRAIN HEK293; CONTROLLED STUDY; DNA SEQUENCE; EMBRYO; ETHNIC DIFFERENCE; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HALF LIFE TIME; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; RNA STABILITY; SEQUENCE ANALYSIS;

3' UNTRANSLATED REGIONS; ANIMALS; CELL LINE; DNA, COMPLEMENTARY; HUMANS; LYMPHOCYTES; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; RNA STABILITY; RNA, MESSENGER;

EID: 37549033138     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017087     Document Type: Article

References (32)

1. Dean JL, Wait R, Mahtani KR, Sully G, Clark AR, and Saklatvala J (2001) The 3′ untranslated region of tumor necrosis factor alpha mRNA is a target of the mRNA-stabilizing factor HuR. Mol Cell Biol 21:721-730.
2. Di Marco S, Hel Z, Lachance C, Furneaux H, and Radzioch D (2001) Polymorphism in the 3′-untranslated region of TNFα mRNA impairs binding of the post-transcriptional regulatory protein HuR to TNFα mRNA. Nucleic Acids Res 29:863-871.
3. Eap CB, Buclin T, and Baumann P (2002) Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 41:1153-1193.
4. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, et al. (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683-3690.
5. Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund S, Kroemer HK, Warzok RW, and Cascorbi I (2007) Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 7:56-65.
6. Hollams EM, Giles KM, Thomson AM, and Leedman PJ (2002) mRNA stability and the control of gene expression: implications for human disease. Neurochem Res 27:957-980.
7. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, et al. (2003) Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13:481-494.
8. Leabman MK, Huang CC, DeYoung J, Carlson EJ, Taylor TR, de la Cruz M, Johns SJ, Stryke D, Kawamoto M, Urban TJ, et al. (2003) Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A 100:5896-5901.
9. Lee CH, Bradley G, and Ling V (1998) Increased P-glycoprotein messenger RNA stability in rat liver tumors in vivo. J Cell Physiol 177:1-12.
10. Lee CH and Ling V (2003) Superinduction of P-glycoprotein messenger RNA in vivo in the presence of transcriptional inhibitors. J Exp Ther Oncol 3:14-26.
11. Lee CH, Rehaume VE, and Shandro J (2005) Identification of in vivo P-glycoprotein mRNA decay intermediates in normal liver but not in liver tumors. J Cell Physiol 204:638-645.
12. Lindell M, Karlsson MO, Lennernas H, Pahlman L, and Lang MA (2003) Variable expression of CYP and Pgp genes in the human small intestine. Eur J Clin Invest 33:493-499.
13. Litman T, Druley TE, Stein WD, and Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931-959.
14. Mangus DA, Evans MC, and Jacobson A (2003) Poly(A)-binding proteins: multifunctional scaffolds for the post-transcriptional control of gene expression. Genome Biol 4:223.
15. Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, Hehl R, Hornischer K, Karas D, Kel AE, Kel-Margoulis OV, et al. (2003) TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 31:374-378.
16. Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N, Shirakawa T, Gotoh A, Fujimoto S, Matsuo M, et al. (2002) Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 25:1356-1359.
17. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, and Okumura K (2002) Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71:297-303.
18. Owen A, Goldring C, Morgan P, Chadwick D, Park BK, and Pirmohamed M (2005) Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol 59:365-370.
19. Peng SS, Chen CY, Xu N, and Shyu AB (1998) RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. EMBO J 17:3461-3470.
20. Pesole G and Liuni S (1999) Internet resources for the functional analysis of 5′ and 3′ untranslated regions of eukaryotic mRNAs. Trends Genet 15:378.
21. Pesole G, Liuni S, Grillo G, Ippedico M, Larizza A, Makalowski W, and Saccone C (1999) UTRdb: a specialized database of 5′ and 3′ untranslated regions of eukaryotic mRNAs. Nucleic Acids Res 27:188-191.
22. Prokipcak RD, Raouf A, and Lee C (1999) The AU-rich 3′ untranslated region of human MDR1 mRNA is an inefficient mRNA destabilizer. Biochem Biophys Res Commun 261:627-634.
23. Schuetz EG, Furuya KN, and Schuetz JD (1995) Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275:1011-1018.
24. Shen LX, Basilion JP, and Stanton VP, Jr (1999) Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc Natl Acad Sci U S A 96:7871-7876.
25. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, and Cascorbi I (2002) The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72:572-583.
26. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, and Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234.
27. Tourriere H, Chebli K, and Tazi J (2002) mRNA degradation machines in eukaryotic cells. Biochimie 84:821-837.
28. Urquhart BL, Tirona RG, and Kim RB (2007) Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 47:566-578.
29. Uwai Y, Masuda S, Goto M, Motohashi H, Saito H, Okuda M, Nakamura E, Ito N, Ogawa O, and Inui K (2004) Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients. J Hum Genet 49:40-45.
30. Wang D, Johnson AD, Papp AC, Kroetz DL, and Sadee W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15:693-704.
31. Wilkie GS, Dickson KS, and Gray NK (2003) Regulation of mRNA translation by 5′- and 3′-UTR-binding factors. Trends Biochem Sci 28:182-188.
32. Yague E, Armesilla AL, Harrison G, Elliott J, Sardini A, Higgins CF, and Raguz S (2003) P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 278:10344-10352.